Sri Vijaya Puram, Aug. 6: The Centre has strengthened India’s drug approval system by introducing stricter penalties against companies and applicants found submitting fake or fabricated data in support of applications under the Drugs Rules, 1945. The amendments empower licensing authorities to reject applications, cancel existing licences and debar offenders from filing fresh applications for a specified period, a move aimed at reinforcing the integrity of the country’s pharmaceutical regulatory framework and safeguarding public health.
The Ministry of Health and Family Welfare (MoHFW) said the new provisions have been notified through amendments to the Drugs Rules, 1945. According to the ministry, the changes are intended to improve transparency, accountability and integrity in the drug approval process by ensuring that regulatory decisions are based on authentic and scientifically valid information.
Under the revised rules, applicants found to have submitted fabricated or misleading data may face multiple regulatory actions. Besides rejection of pending applications or cancellation of licences already granted, the licensing authority can also debar such applicants from submitting fresh applications before the concerned regulatory authority for a specified period.
The ministry said the amended framework also incorporates procedural safeguards before any punitive action is taken. Authorities must first issue a show-cause notice to the concerned applicant, providing an opportunity to respond. The revised rules further include a provision allowing applicants to file an appeal against any action taken under the new provisions.
Explaining the rationale behind the amendments, the ministry said scientific data submitted by applicants forms the foundation for evaluating the quality, safety and efficacy of medicines before regulatory approval is granted. It said the submission of fake or fabricated data undermines the integrity of the regulatory process, raises concerns about the quality of drugs and may pose serious risks to public health.
According to the government, the amendments are designed to deter regulatory malpractice, strengthen accountability among applicants and ensure that drug approvals are supported by credible scientific evidence. The revised provisions are also intended to encourage greater compliance among drug manufacturers and distributors while creating stronger deterrents against entities involved in regulatory misconduct.
The government said the latest amendments form part of its broader efforts to strengthen India’s pharmaceutical regulatory framework in line with global best practices. It added that the reforms complement ongoing measures aimed at enhancing regulatory oversight, promoting ethical practices across the pharmaceutical sector and ensuring appropriate penalties for violations under the Drugs Rules, 1945.
